Clinical Trial Update: Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase II trial update for Trilaciclib in combination with pembrolizumab, gemcitabine, and carboplatin in metastatic triple-negative breast cancer; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Cosela (trilaciclib)
• Gemzar (gemcitabine)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Metastatic Triple-Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING